Business Context and Reporting Period
Company: CryoLife, Inc. (Note: Request metadata listed "Artivion, Inc." but the filing text identifies the registrant as CryoLife, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the three months ended March 31, 1997.
Business Overview: CryoLife specializes in cryopreservation of human tissues (heart valves, veins, orthopaedic) and medical devices. The quarter was significantly impacted by the acquisition of Ideas for Medicine, Inc. (IFM), a manufacturer of single-use cardiovascular products, on March 5, 1997.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Total Revenues | $10,413,000 | $8,434,000 |
| Net Income | $952,000 | $782,000 |
| Earnings Per Share (Basic) | $0.10 | $0.08 |
| Operating Cash Flow | $(2,259,000) | $343,000 |
| Cost of Preservation/Products Margin | 33% of Revenue | 34% of Revenue |
| Total Assets | $47,063,000 | $34,973,000 (Dec 31, 1996) |
| Total Liabilities | $21,053,000 | $10,044,000 (Dec 31, 1996) |
| Shareholders' Equity | $26,010,000 | $24,929,000 (Dec 31, 1996) |
| Cash and Equivalents | $192,000 | $1,370,000 (Dec 31, 1996) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 24% to $10.4 million. This includes $554,000 from the IFM acquisition. Organic growth was driven by a 15% increase in allograft shipments and a fee increase in January 1997.
- Segment Performance:
- Heart Valves: Revenue up 18% to $6.5 million (62% of total); shipments up 17%.
- Veins: Revenue up 44% to $2.6 million (25% of total); shipments up 43%.
- Orthopaedic: Revenue down 8% to $693,000 due to limited tissue availability.
- Other: Revenue down 83% due to a decrease in research grants.
- Acquisition Impact: The acquisition of IFM resulted in a significant increase in debt ($5 million convertible debentures + cash financing) and goodwill ($8.7 million recorded). Total debt increased from $1.5 million (long-term) + $1.25 million (line of credit) at year-end 1996 to $14.5 million in total debt obligations at March 31, 1997.
- Cash Flow: Operating cash flow turned negative ($2.3 million outflow) compared to a positive $343,000 in the prior year, primarily due to increases in receivables, deferred preservation costs, and inventory, alongside a decrease in accounts payable.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash from operations and approximately $1.8 million of remaining borrowing capacity under a $10 million credit facility will meet future needs. This includes funding for a new $1 million manufacturing facility for IFM.
- Seasonality: Demand for heart valve preservation is seasonal, peaking in the second and third quarters due to pediatric surgeries.
- Risks: Key risks include government regulation, competitive position, tissue availability, product development status, intellectual property protection, third-party reimbursement rates, and the successful integration of IFM operations.
- Capital Allocation: The company authorized a potential repurchase of up to 500,000 shares of common stock on April 2, 1997.
Investor Verification Checklist
- Acquisition Integration: Verify the successful operational integration of Ideas for Medicine, Inc. (IFM) and the realization of projected synergies.
- Debt Service: Confirm the company's ability to service the new $5 million convertible debenture and increased revolving credit line obligations.
- Cash Position: Monitor the low cash balance ($192,000) relative to the negative operating cash flow and upcoming capital expenditures.
- Tissue Supply: Assess the impact of tissue availability constraints on the orthopaedic segment and overall growth.
- Accounting Changes: Note the upcoming adoption of FASB Statement No. 128 (Earnings per Share) effective December 31, 1997, which will alter EPS calculations.